Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ariad to gross up to $345m from stock offer to fund Iclusig commercialization

This article was originally published in Scrip

Executive Summary

Ariad Pharmaceuticals will raise at least $300 million in an offering of 15.3 million common stock shares priced at $19.60 per share to finance sales, manufacturing and distribution of the kinase inhibitor Iclusig (ponatinib), which won US FDA approval on 14 December to treat chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) (scripintelligence.com, 15 December 2012).

Related Companies

UsernamePublicRestriction

Register

SC020176

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel